Answers are grounded in this paper and cite their sources.
Introduction Checkpoint inhibitor pneumonitis (CIP) is a potentially life-threatening adverse event caused by anti–programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) antibodies. However, paradoxical findings have been reported regarding the association between overall survival (OS) and CIP. This study aimed to prospectively evaluate the relationship between the 2-year OS and CIP in patients receiving first-line treatment, including anti-PD-1/PD-L1 antibody therapy, using 3-month and 1-year landmark analyses. Methods A multicenter prospective observational study was conducted between December 2021 and November 2023 to evaluate the prognostic impact of CIP, based on timing and severity, in patients with non-small cell lung cancer (NSCLC). Results Although no significant difference in OS was observed between patients with and without CIP developed within 2 years or 1 year, the 3-month landmark analysis showed that patients who developed CIP within 3 months had significantly shorter OS than those who did not (median OS from the 3-months landmark: 11.1 months with CIP versus not reached without CIP; log-rank p = 0.011). In multivariate Cox regression analyses, using patients without CIP as the reference group, CIP within 3 months was significantly associated with impaired overall survival (any-grade CIP: hazard ratio [HR] = 2.22, 95% confidence interval [CI]=1.21–4.09; Grade 3–5 CIP: HR=3.37, 95% CI=1.57–7.23). Conclusion This was the first prospective study to demonstrate the prognostic value of CIP. CIP within 3 months after the initiation of first-line treatment, including anti-PD-1/PD-L1 antibody, especially Grade 3–5 CIP, was associated with shorter OS in patients with NSCLC.
No takes yet. Share an insight, caveat, or question.
Yamaguchi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: